Cargando…
Robust Antibody Levels in Both Diabetic and Non-Diabetic Individuals After BNT162b2 mRNA COVID-19 Vaccination
The emergence of effective vaccines for COVID-19 has been welcomed by the world with great optimism. Given their increased susceptibility to COVID-19, the question arises whether individuals with type-2 diabetes mellitus (T2DM) and other metabolic conditions can respond effectively to the mRNA-based...
Autores principales: | , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8652288/ https://www.ncbi.nlm.nih.gov/pubmed/34899701 http://dx.doi.org/10.3389/fimmu.2021.752233 |
_version_ | 1784611564395954176 |
---|---|
author | Ali, Hamad Alterki, Abdulmohsen Sindhu, Sardar Alahmad, Barrak Hammad, Maha Al-Sabah, Salman Alghounaim, Mohammad Jamal, Mohammad H. Aldei, Ali Mairza, Mohammad J. Husain, Maitham Deverajan, Sriraman Ahmad, Rasheed Cherian, Preethi Alkhairi, Irina Alkandari, Abdullah Abubaker, Jehad Abu-Farha, Mohamed Al-Mulla, Fahd |
author_facet | Ali, Hamad Alterki, Abdulmohsen Sindhu, Sardar Alahmad, Barrak Hammad, Maha Al-Sabah, Salman Alghounaim, Mohammad Jamal, Mohammad H. Aldei, Ali Mairza, Mohammad J. Husain, Maitham Deverajan, Sriraman Ahmad, Rasheed Cherian, Preethi Alkhairi, Irina Alkandari, Abdullah Abubaker, Jehad Abu-Farha, Mohamed Al-Mulla, Fahd |
author_sort | Ali, Hamad |
collection | PubMed |
description | The emergence of effective vaccines for COVID-19 has been welcomed by the world with great optimism. Given their increased susceptibility to COVID-19, the question arises whether individuals with type-2 diabetes mellitus (T2DM) and other metabolic conditions can respond effectively to the mRNA-based vaccine. We aimed to evaluate the levels of anti-SARS-CoV-2 IgG and neutralizing antibodies in people with T2DM and/or other metabolic risk factors (hypertension and obesity) compared to those without. This study included 262 people (81 diabetic and 181 non-diabetic persons) that took two doses of BNT162b2 (Pfizer–BioNTech) mRNA vaccine. Both T2DM and non-diabetic individuals had a robust response to vaccination as demonstrated by their high antibody titers. However, both SARS-CoV-2 IgG and neutralizing antibodies titers were lower in people with T2DM. The mean ( ± 1 standard deviation) levels were 154 ± 49.1 vs. 138 ± 59.4 BAU/ml for IgG and 87.1 ± 11.6 vs. 79.7 ± 19.5% for neutralizing antibodies in individuals without diabetes compared to those with T2DM, respectively. In a multiple linear regression adjusted for individual characteristics, comorbidities, previous COVID-19 infection, and duration since second vaccine dose, diabetics had 13.86 BAU/ml (95% CI: 27.08 to 0.64 BAU/ml, p=0.041) less IgG antibodies and 4.42% (95% CI: 8.53 to 0.32%, p=0.036) fewer neutralizing antibodies than non-diabetics. Hypertension and obesity did not show significant changes in antibody titers. Taken together, both type-2 diabetic and non-diabetic individuals elicited strong immune responses to SARS-CoV-2 BNT162b2 mRNA vaccine; nonetheless, lower levels were seen in people with diabetes. Continuous monitoring of the antibody levels might be a good indicator to guide personalized needs for further booster shots to maintain adaptive immunity. Nonetheless, it is important that people get their COVID-19 vaccination especially people with diabetes. |
format | Online Article Text |
id | pubmed-8652288 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-86522882021-12-09 Robust Antibody Levels in Both Diabetic and Non-Diabetic Individuals After BNT162b2 mRNA COVID-19 Vaccination Ali, Hamad Alterki, Abdulmohsen Sindhu, Sardar Alahmad, Barrak Hammad, Maha Al-Sabah, Salman Alghounaim, Mohammad Jamal, Mohammad H. Aldei, Ali Mairza, Mohammad J. Husain, Maitham Deverajan, Sriraman Ahmad, Rasheed Cherian, Preethi Alkhairi, Irina Alkandari, Abdullah Abubaker, Jehad Abu-Farha, Mohamed Al-Mulla, Fahd Front Immunol Immunology The emergence of effective vaccines for COVID-19 has been welcomed by the world with great optimism. Given their increased susceptibility to COVID-19, the question arises whether individuals with type-2 diabetes mellitus (T2DM) and other metabolic conditions can respond effectively to the mRNA-based vaccine. We aimed to evaluate the levels of anti-SARS-CoV-2 IgG and neutralizing antibodies in people with T2DM and/or other metabolic risk factors (hypertension and obesity) compared to those without. This study included 262 people (81 diabetic and 181 non-diabetic persons) that took two doses of BNT162b2 (Pfizer–BioNTech) mRNA vaccine. Both T2DM and non-diabetic individuals had a robust response to vaccination as demonstrated by their high antibody titers. However, both SARS-CoV-2 IgG and neutralizing antibodies titers were lower in people with T2DM. The mean ( ± 1 standard deviation) levels were 154 ± 49.1 vs. 138 ± 59.4 BAU/ml for IgG and 87.1 ± 11.6 vs. 79.7 ± 19.5% for neutralizing antibodies in individuals without diabetes compared to those with T2DM, respectively. In a multiple linear regression adjusted for individual characteristics, comorbidities, previous COVID-19 infection, and duration since second vaccine dose, diabetics had 13.86 BAU/ml (95% CI: 27.08 to 0.64 BAU/ml, p=0.041) less IgG antibodies and 4.42% (95% CI: 8.53 to 0.32%, p=0.036) fewer neutralizing antibodies than non-diabetics. Hypertension and obesity did not show significant changes in antibody titers. Taken together, both type-2 diabetic and non-diabetic individuals elicited strong immune responses to SARS-CoV-2 BNT162b2 mRNA vaccine; nonetheless, lower levels were seen in people with diabetes. Continuous monitoring of the antibody levels might be a good indicator to guide personalized needs for further booster shots to maintain adaptive immunity. Nonetheless, it is important that people get their COVID-19 vaccination especially people with diabetes. Frontiers Media S.A. 2021-11-24 /pmc/articles/PMC8652288/ /pubmed/34899701 http://dx.doi.org/10.3389/fimmu.2021.752233 Text en Copyright © 2021 Ali, Alterki, Sindhu, Alahmad, Hammad, Al-Sabah, Alghounaim, Jamal, Aldei, Mairza, Husain, Deverajan, Ahmad, Cherian, Alkhairi, Alkandari, Abubaker, Abu-Farha and Al-Mulla https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Ali, Hamad Alterki, Abdulmohsen Sindhu, Sardar Alahmad, Barrak Hammad, Maha Al-Sabah, Salman Alghounaim, Mohammad Jamal, Mohammad H. Aldei, Ali Mairza, Mohammad J. Husain, Maitham Deverajan, Sriraman Ahmad, Rasheed Cherian, Preethi Alkhairi, Irina Alkandari, Abdullah Abubaker, Jehad Abu-Farha, Mohamed Al-Mulla, Fahd Robust Antibody Levels in Both Diabetic and Non-Diabetic Individuals After BNT162b2 mRNA COVID-19 Vaccination |
title | Robust Antibody Levels in Both Diabetic and Non-Diabetic Individuals After BNT162b2 mRNA COVID-19 Vaccination |
title_full | Robust Antibody Levels in Both Diabetic and Non-Diabetic Individuals After BNT162b2 mRNA COVID-19 Vaccination |
title_fullStr | Robust Antibody Levels in Both Diabetic and Non-Diabetic Individuals After BNT162b2 mRNA COVID-19 Vaccination |
title_full_unstemmed | Robust Antibody Levels in Both Diabetic and Non-Diabetic Individuals After BNT162b2 mRNA COVID-19 Vaccination |
title_short | Robust Antibody Levels in Both Diabetic and Non-Diabetic Individuals After BNT162b2 mRNA COVID-19 Vaccination |
title_sort | robust antibody levels in both diabetic and non-diabetic individuals after bnt162b2 mrna covid-19 vaccination |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8652288/ https://www.ncbi.nlm.nih.gov/pubmed/34899701 http://dx.doi.org/10.3389/fimmu.2021.752233 |
work_keys_str_mv | AT alihamad robustantibodylevelsinbothdiabeticandnondiabeticindividualsafterbnt162b2mrnacovid19vaccination AT alterkiabdulmohsen robustantibodylevelsinbothdiabeticandnondiabeticindividualsafterbnt162b2mrnacovid19vaccination AT sindhusardar robustantibodylevelsinbothdiabeticandnondiabeticindividualsafterbnt162b2mrnacovid19vaccination AT alahmadbarrak robustantibodylevelsinbothdiabeticandnondiabeticindividualsafterbnt162b2mrnacovid19vaccination AT hammadmaha robustantibodylevelsinbothdiabeticandnondiabeticindividualsafterbnt162b2mrnacovid19vaccination AT alsabahsalman robustantibodylevelsinbothdiabeticandnondiabeticindividualsafterbnt162b2mrnacovid19vaccination AT alghounaimmohammad robustantibodylevelsinbothdiabeticandnondiabeticindividualsafterbnt162b2mrnacovid19vaccination AT jamalmohammadh robustantibodylevelsinbothdiabeticandnondiabeticindividualsafterbnt162b2mrnacovid19vaccination AT aldeiali robustantibodylevelsinbothdiabeticandnondiabeticindividualsafterbnt162b2mrnacovid19vaccination AT mairzamohammadj robustantibodylevelsinbothdiabeticandnondiabeticindividualsafterbnt162b2mrnacovid19vaccination AT husainmaitham robustantibodylevelsinbothdiabeticandnondiabeticindividualsafterbnt162b2mrnacovid19vaccination AT deverajansriraman robustantibodylevelsinbothdiabeticandnondiabeticindividualsafterbnt162b2mrnacovid19vaccination AT ahmadrasheed robustantibodylevelsinbothdiabeticandnondiabeticindividualsafterbnt162b2mrnacovid19vaccination AT cherianpreethi robustantibodylevelsinbothdiabeticandnondiabeticindividualsafterbnt162b2mrnacovid19vaccination AT alkhairiirina robustantibodylevelsinbothdiabeticandnondiabeticindividualsafterbnt162b2mrnacovid19vaccination AT alkandariabdullah robustantibodylevelsinbothdiabeticandnondiabeticindividualsafterbnt162b2mrnacovid19vaccination AT abubakerjehad robustantibodylevelsinbothdiabeticandnondiabeticindividualsafterbnt162b2mrnacovid19vaccination AT abufarhamohamed robustantibodylevelsinbothdiabeticandnondiabeticindividualsafterbnt162b2mrnacovid19vaccination AT almullafahd robustantibodylevelsinbothdiabeticandnondiabeticindividualsafterbnt162b2mrnacovid19vaccination |